Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.

Ninou I, Kaffe E, Müller S, Budd DC, Stevenson CS, Ullmer C, Aidinis V.

Pulm Pharmacol Ther. 2018 Oct;52:32-40. doi: 10.1016/j.pupt.2018.08.003. Epub 2018 Sep 7.

PMID:
30201409
2.

NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS.

Ouali Alami N, Schurr C, Olde Heuvel F, Tang L, Li Q, Tasdogan A, Kimbara A, Nettekoven M, Ottaviani G, Raposo C, Röver S, Rogers-Evans M, Rothenhäusler B, Ullmer C, Fingerle J, Grether U, Knuesel I, Boeckers TM, Ludolph A, Wirth T, Roselli F, Baumann B.

EMBO J. 2018 Aug 15;37(16). pii: e98697. doi: 10.15252/embj.201798697. Epub 2018 Jun 6.

3.

Lysophosphatidic Acid Induces ECM Production via Activation of the Mechanosensitive YAP/TAZ Transcriptional Pathway in Trabecular Meshwork Cells.

Ho LTY, Skiba N, Ullmer C, Rao PV.

Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):1969-1984. doi: 10.1167/iovs.17-23702.

4.

From Structure-Activity Relationships on Thiazole Derivatives to the In Vivo Evaluation of a New Radiotracer for Cannabinoid Subtype 2 PET Imaging.

Caillé F, Cacheux F, Peyronneau MA, Jego B, Jaumain E, Pottier G, Ullmer C, Grether U, Winkeler A, Dollé F, Damont A, Kuhnast B.

Mol Pharm. 2017 Nov 6;14(11):4064-4078. doi: 10.1021/acs.molpharmaceut.7b00746. Epub 2017 Oct 18.

PMID:
28968497
5.

A Novel Selective Inverse Agonist of the CB2 Receptor as a Radiolabeled Tool Compound for Kinetic Binding Studies.

Martella A, Sijben H, Rufer AC, Grether U, Fingerle J, Ullmer C, Hartung T, IJzerman AP, van der Stelt M, Heitman LH.

Mol Pharmacol. 2017 Oct;92(4):389-400. doi: 10.1124/mol.117.108605. Epub 2017 Jul 26.

6.

Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity.

Soethoudt M, Grether U, Fingerle J, Grim TW, Fezza F, de Petrocellis L, Ullmer C, Rothenhäusler B, Perret C, van Gils N, Finlay D, MacDonald C, Chicca A, Gens MD, Stuart J, de Vries H, Mastrangelo N, Xia L, Alachouzos G, Baggelaar MP, Martella A, Mock ED, Deng H, Heitman LH, Connor M, Di Marzo V, Gertsch J, Lichtman AH, Maccarrone M, Pacher P, Glass M, van der Stelt M.

Nat Commun. 2017 Jan 3;8:13958. doi: 10.1038/ncomms13958.

7.

Synthesis, Biodistribution and In vitro Evaluation of Brain Permeable High Affinity Type 2 Cannabinoid Receptor Agonists [11C]MA2 and [18F]MA3.

Ahamed M, van Veghel D, Ullmer C, Van Laere K, Verbruggen A, Bormans GM.

Front Neurosci. 2016 Sep 22;10:431. eCollection 2016.

8.

LYSOPHOSPHATIDIC ACIDS AND AUTOTAXIN IN RETINAL VEIN OCCLUSION.

Dacheva I, Ullmer C, Ceglowska K, Nogoceke E, Hartmann G, Müller S, Rejdak R, Nowomiejska K, Reich M, Nobl M, Tandogan T, Kretz FT, Auffarth GU, Koss MJ.

Retina. 2016 Dec;36(12):2311-2318.

PMID:
27648638
9.

Incretin-like effects of small molecule trace amine-associated receptor 1 agonists.

Raab S, Wang H, Uhles S, Cole N, Alvarez-Sanchez R, Künnecke B, Ullmer C, Matile H, Bedoucha M, Norcross RD, Ottaway-Parker N, Perez-Tilve D, Conde Knape K, Tschöp MH, Hoener MC, Sewing S.

Mol Metab. 2015 Nov 1;5(1):47-56. doi: 10.1016/j.molmet.2015.09.015. eCollection 2016 Jan.

10.

TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro.

Reich M, Deutschmann K, Sommerfeld A, Klindt C, Kluge S, Kubitz R, Ullmer C, Knoefel WT, Herebian D, Mayatepek E, Häussinger D, Keitel V.

Gut. 2016 Mar;65(3):487-501. doi: 10.1136/gutjnl-2015-309458. Epub 2015 Sep 29.

PMID:
26420419
11.

Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases.

Nettekoven M, Adam JM, Bendels S, Bissantz C, Fingerle J, Grether U, Grüner S, Guba W, Kimbara A, Ottaviani G, Püllmann B, Rogers-Evans M, Röver S, Rothenhäusler B, Schmitt S, Schuler F, Schulz-Gasch T, Ullmer C.

ChemMedChem. 2016 Jan 19;11(2):179-89. doi: 10.1002/cmdc.201500218. Epub 2015 Jul 21.

PMID:
26228928
12.

Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor.

Slavik R, Grether U, Müller Herde A, Gobbi L, Fingerle J, Ullmer C, Krämer SD, Schibli R, Mu L, Ametamey SM.

J Med Chem. 2015 May 28;58(10):4266-77. doi: 10.1021/acs.jmedchem.5b00283. Epub 2015 May 14.

PMID:
25950914
13.

BF-1--a novel selective 5-HT2B receptor antagonist blocking neurogenic dural plasma protein extravasation in guinea pigs.

Schmitz B, Ullmer C, Segelcke D, Gwarek M, Zhu XR, Lübbert H.

Eur J Pharmacol. 2015 Mar 15;751:73-80. doi: 10.1016/j.ejphar.2015.01.043. Epub 2015 Feb 7.

PMID:
25666387
14.

6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds.

Röver S, Andjelkovic M, Bénardeau A, Chaput E, Guba W, Hebeisen P, Mohr S, Nettekoven M, Obst U, Richter WF, Ullmer C, Waldmeier P, Wright MB.

J Med Chem. 2013 Dec 27;56(24):9874-96. doi: 10.1021/jm4010708. Epub 2013 Nov 20.

PMID:
24175572
15.

Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.

Dehmlow H, Alvarez Sánchez R, Bachmann S, Bissantz C, Bliss F, Conde-Knape K, Graf M, Martin RE, Obst Sander U, Raab S, Richter HG, Sewing S, Sprecher U, Ullmer C, Mattei P.

Bioorg Med Chem Lett. 2013 Aug 15;23(16):4627-32. doi: 10.1016/j.bmcl.2013.06.017. Epub 2013 Jun 19.

PMID:
23831134
16.

Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release.

Ullmer C, Alvarez Sanchez R, Sprecher U, Raab S, Mattei P, Dehmlow H, Sewing S, Iglesias A, Beauchamp J, Conde-Knape K.

Br J Pharmacol. 2013 Jun;169(3):671-84. doi: 10.1111/bph.12158.

17.

Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening.

Nettekoven M, Fingerle J, Grether U, Grüner S, Kimbara A, Püllmann B, Rogers-Evans M, Röver S, Schuler F, Schulz-Gasch T, Ullmer C.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1177-81. doi: 10.1016/j.bmcl.2013.01.044. Epub 2013 Jan 23.

PMID:
23380378
18.

2-Phenoxy-nicotinamides are potent agonists at the bile acid receptor GPBAR1 (TGR5).

Martin RE, Bissantz C, Gavelle O, Kuratli C, Dehmlow H, Richter HG, Obst Sander U, Erickson SD, Kim K, Pietranico-Cole SL, Alvarez-Sánchez R, Ullmer C.

ChemMedChem. 2013 Apr;8(4):569-76. doi: 10.1002/cmdc.201200474. Epub 2012 Dec 7.

PMID:
23225346
19.

Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7.

Ullmer C, Zoffmann S, Bohrmann B, Matile H, Lindemann L, Flor P, Malherbe P.

Br J Pharmacol. 2012 Dec;167(7):1448-66. doi: 10.1111/j.1476-5381.2012.02090.x.

20.

Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.

Richter HG, Freichel C, Huwyler J, Nakagawa T, Nettekoven M, Plancher JM, Raab S, Roche O, Schuler F, Taylor S, Ullmer C, Wiegand R.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5713-7. doi: 10.1016/j.bmcl.2010.08.009. Epub 2010 Aug 6.

PMID:
20801030
21.

The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes.

Keitel V, Ullmer C, Häussinger D.

Biol Chem. 2010 Jul;391(7):785-9. doi: 10.1515/BC.2010.077.

PMID:
20623999
22.

The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders.

Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Häussinger D.

Hepatology. 2009 Sep;50(3):861-70. doi: 10.1002/hep.23032.

PMID:
19582812
23.

5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity.

Pierson PD, Fettes A, Freichel C, Gatti-McArthur S, Hertel C, Huwyler J, Mohr P, Nakagawa T, Nettekoven M, Plancher JM, Raab S, Richter H, Roche O, Rodríguez Sarmiento RM, Schmitt M, Schuler F, Takahashi T, Taylor S, Ullmer C, Wiegand R.

J Med Chem. 2009 Jul 9;52(13):3855-68. doi: 10.1021/jm900409x.

PMID:
19456097
24.

The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.

Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86. doi: 10.1007/s00210-008-0341-4. Epub 2008 Aug 14.

PMID:
18704368
25.

Influence of different promoters on the expression pattern of mutated human alpha-synuclein in transgenic mice.

Maskri L, Zhu X, Fritzen S, Kühn K, Ullmer C, Engels P, Andriske M, Stichel CC, Lübbert H.

Neurodegener Dis. 2004;1(6):255-65.

26.

Expression of MUPP1 protein in mouse brain.

Sitek B, Poschmann G, Schmidtke K, Ullmer C, Maskri L, Andriske M, Stichel CC, Zhu XR, Luebbert H.

Brain Res. 2003 Apr 25;970(1-2):178-87.

PMID:
12706259
27.

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

Samochocki M, Höffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lübbert H, Albuquerque EX, Maelicke A.

J Pharmacol Exp Ther. 2003 Jun;305(3):1024-36. Epub 2003 Mar 20.

28.

Antagonist effect of pseudohypericin at CRF1 receptors.

Simmen U, Bobirnac I, Ullmer C, Lübbert H, Berger Büter K, Schaffner W, Schoeffter P.

Eur J Pharmacol. 2003 Jan 5;458(3):251-6.

PMID:
12504780
29.

Distinct claudins and associated PDZ proteins form different autotypic tight junctions in myelinating Schwann cells.

Poliak S, Matlis S, Ullmer C, Scherer SS, Peles E.

J Cell Biol. 2002 Oct 28;159(2):361-72. Epub 2002 Oct 28.

30.

Synaptic multiprotein complexes associated with 5-HT(2C) receptors: a proteomic approach.

Bécamel C, Alonso G, Galéotti N, Demey E, Jouin P, Ullmer C, Dumuis A, Bockaert J, Marin P.

EMBO J. 2002 May 15;21(10):2332-42.

31.

Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1.

Becamel C, Figge A, Poliak S, Dumuis A, Peles E, Bockaert J, Lubbert H, Ullmer C.

J Biol Chem. 2001 Apr 20;276(16):12974-82. Epub 2001 Jan 9.

32.

Parkin expression in the adult mouse brain.

Stichel CC, Augustin M, Kühn K, Zhu XR, Engels P, Ullmer C, Lübbert H.

Eur J Neurosci. 2000 Dec;12(12):4181-94.

PMID:
11122330
33.

Cloning and characterization of MUPP1, a novel PDZ domain protein.

Ullmer C, Schmuck K, Figge A, Lübbert H.

FEBS Lett. 1998 Mar 6;424(1-2):63-8.

34.

Localization of the human CRF2 receptor to 7p21-p15 by radiation hybrid mapping and FISH analysis.

Meyer AH, Ullmer C, Schmuck K, Morel C, Wishart W, Lübbert H, Engels P.

Genomics. 1997 Feb 15;40(1):189-90. No abstract available.

PMID:
9070940
35.

Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice.

Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lübbert H, Bujard H.

Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8.

36.

Distribution of 5-HT4 receptor mRNA in the rat brain.

Ullmer C, Engels P, Abdel'Al S, Lübbert H.

Naunyn Schmiedebergs Arch Pharmacol. 1996 Jul;354(2):210-2.

PMID:
8857600
37.

Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache?

Schmuck K, Ullmer C, Kalkman HO, Probst A, Lubbert H.

Eur J Neurosci. 1996 May;8(5):959-67.

PMID:
8743744
38.
39.

Functional, endogenously expressed 5-hydroxytryptamine 5-ht7 receptors in human vascular smooth muscle cells.

Schoeffter P, Ullmer C, Bobirnac I, Gabbiani G, Lübbert H.

Br J Pharmacol. 1996 Mar;117(6):993-4.

40.

Functional serotonin 5-HT1D receptors and 5-HT1D beta receptor mRNA expression in human umbilical vein endothelial cells.

Schoeffter P, Ullmer C, Gutierrez M, Weitz-Schmidt G, Lübbert H.

Naunyn Schmiedebergs Arch Pharmacol. 1995 Nov;352(5):580-2.

PMID:
8751089
41.

Expression of serotonin receptor mRNAs in blood vessels.

Ullmer C, Schmuck K, Kalkman HO, Lübbert H.

FEBS Lett. 1995 Aug 21;370(3):215-21.

42.

Differential transactivation potential of Oct1 and Oct2 is determined by additional B cell-specific activities.

Pfisterer P, Annweiler A, Ullmer C, Corcoran LM, Wirth T.

EMBO J. 1994 Apr 1;13(7):1654-63.

43.

Cloning and functional characterization of the human 5-HT2B serotonin receptor.

Schmuck K, Ullmer C, Engels P, Lübbert H.

FEBS Lett. 1994 Mar 28;342(1):85-90.

Supplemental Content

Loading ...
Support Center